Top Industry Leaders in the Osteomyelitis Market
Latest Osteomyelitis Companies Update
September 2023: A Phase II trial begins evaluating the efficacy of phage therapy for treating chronic osteomyelitis, exploring a potential alternative to traditional antibiotics.August 2023: Researchers at the University of Pennsylvania develop a new imaging technique for early detection of osteomyelitis, potentially improving diagnosis and treatment outcomes.July 2023: A study published in Nature Reviews Rheumatology highlights the importance of personalized medicine approaches in managing osteomyelitis based on individual patient factors and microbial pathogens.July 2023: Osteotech Inc. receives FDA clearance for its OsteoGraf-DBM PLUS bone growth stimulator with integrated demineralized bone matrix, aiming to enhance bone healing in osteomyelitis patients.June 2023: K2M receives FDA approval for its Mobi-C cervical artificial disc, potentially offering a long-term solution for treating spinal osteomyelitis and preventing complications.April 2023: Merck launches Zeptera™ (ceftobiprole medoxomil), a new antibiotic specifically indicated for diabetic foot infections, a common form of osteomyelitis.
List of Osteomyelitis Key Companies in the Market
- Allergan Plc (Republic of Ireland)
- CrystalGenomics Inc (South Korea)
- Debiopharm International SA (Lausanne)
- Motif Bio Plc (London)
- Nabriva Therapeutics AG (Dublin)
- Vyome Biosciences Pvt Ltd (India)
- F. Hoffmann-La Roche AG (Switzerland)
- Koninklijke Philips N.V. (Netherlands)
- General Healthcare (U.S.)
- Siemens AG (Germany)
- Toshiba Corporation (Japan)
- Shimadzu Corporation (Japan)
- Samsung Electronics Co., Ltd. (South Korea)
- Neusoft Medical Systems Co., Ltd. (China)
- Medtronic plc (Ireland)
- Shenzhen Anke High-tech Co., Ltd. (Hong Kong)